Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30 results about "PIK3CA Gene Mutation" patented technology

A molecular genetic abnormality indicating the presence of a mutation in the PI3KCA (phosphatidyl inositol 3-kinase) gene on chromosome 3q26.32.

Reagent kit used for testing PIK3CA (phosphatidylinositol-4,5-bisphosphate3-kinase, catalytic subunit alpha) gene mutations

The invention is applicable to biotechnology and the medical field and relates to a reagent kit used for testing PIK3CA (phosphatidylinositol-4,5-bisphosphate3-kinase, catalytic subunit alpha) gene mutations. A first reagent, a second reagent, a third reagent, a fourth reagent and a fifth reagent are sequentially targeted to E542K, E545K, E545D, H1047R and H1047L mutations of a PIK3CA gene, and a sixth reagent is targeted to a conserved region of the PIK3CA gene and used for quality control. A testing method is carried out by the testing reagent kit by means of fluorescence quantitative PCR (polymerase chain reaction). The testing reagent kit is high in sensitivity and good in specificity and is a high-performance human PIK3CA gene mutation testing reagent kit. The fluorescence quantitative PCR method is adopted for performing specific amplification testing on sequences in PIK3CA gene mutation regions, and specific binding of the MGB (minor groove binder) blocked nucleic acid and a wild type DNA (deoxyribo nucleic acid) template in a sample to be tested is utilized to inhibit binding of the wild type DNA template and a primer probe. Forward primers are designed by methods of lowering the primer Tm value, tailing the 5' end and adding and inserting bases among the primers and the like, specificity of the reagent kit can be improved, then more than 45 cycle numbers are introduced, and accordingly effect of improving sensitivity of the regent kit is achieved.
Owner:WUHAN YZY MEDICAL SCI & TECH

Detection of mutation site of PIK3CA gene in ctDNA in urine

The invention relates to detection of a mutation site of a PIK3CA gene in the ctDNA in urine, and particularly provides a method for separating the ctDNA from a urine sample, a method for building a sequencing library based on the urine sample, a method for performing nucleic acid sequencing based on the urine sample according to the sequencing library, equipment for separating the ctDNA from theurine sample and a system for determining the sensitivity of an individual drug. The method for separating the ctDNA from the urine sample comprises the following steps: adding EDTA into the urine sample to obtain a first mixed solution; centrifugating the mixed solution, and collecting supernate; concentrating the supernate to obtain a concentrated solution; mixing the concentrated solution withanion exchange resin to obtain a second mixed solution; performing chromatographic separation treatment on the second mixed solution to obtain eluent; purifying the eluent to obtain the ctDNA. According to the detection disclosed by the invention, a large quantity of ctDNAs can be extracted quickly from a large quantity of urine samples, and can be subjected to nucleic acid sequencing, and the sensitivity of the individual drug can be determined, so that the application prospect of the ctDNA in the urine is enlarged.
Owner:索真(北京)医学科技有限公司

Probes, primers and kits for detecting five mutations of human pik3ca gene

The invention discloses primers and probes and a kit for detecting five mutation types of a human PIK3CA gene. According to each group of the five groups (PIM1-PIM5) of the primers and probes, the mutation primer can be combined with a conserved sequence of the PIK3CA gene, a mutation ARMS primer can be specially combined with a corresponding mutation sequence of the mutation ARMS primer to amplify the mutation sequence, the detection probe can be combined with an amplified fragment, and the blocking probe can be specially combined with a wild type sequence corresponding to a mutation locus to inhibit wild type nonspecific amplification. Accordingly, by adopting a specific mutation primer and probe blocking technology, the five mutation types of the PIK3CA gene can be accurately detected; through the established kit of a real-time fluorescence PCR amplification reaction system, rapid detection on the PIK3CA gene mutation is facilitated, operation is easy, and a result is easy to read; the detection method is high in sensitivity, and 50-copy mutation can be stably detected; the specificity is good, no nonspecific amplification is generated in 20-ng wild type genome DNA, and the detectability reaches up to 1%.
Owner:武汉海吉力生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products